Literature DB >> 8175190

Urinary platinum in hospital personnel occupationally exposed to platinum-containing antineoplastic drugs.

A S Ensslin1, A Pethran, R Schierl, G Fruhmann.   

Abstract

Urinary platinum levels of 21 nurses and hospital pharmacy personnel occupationally exposed to platinum containing antineoplastic drugs were determined in 24-h urine by voltammetric analysis after UV photolysis. All study participants applied standard safety measures, including a vertical laminar air-flow cabinet and latex gloves. The amount of platinum-containing drugs prepared for intravenous application ranged from 40-3260 mg/day. Urinary platinum was detected in 9 of 52 urine samples collected on days when platinum-containing drugs were mixed (limit of determination 4 ng/l). In comparison with a non-exposed control group, elevated urinary platinum levels were found in one pharmacist (35 ng/g creatinine) and one pharmacy technician (28 ng/g creatinine). The pharmacist's urinary platinum remained elevated after 2 days without occupational exposure to antineoplastic drugs. The urinary platinum level of the pharmacy technician dropped considerably after several weeks without handling cytostatic drugs. Voltammetric detection of urinary platinum is a highly sensitive method suitable for biological and environmental monitoring.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8175190     DOI: 10.1007/bf00405699

Source DB:  PubMed          Journal:  Int Arch Occup Environ Health        ISSN: 0340-0131            Impact factor:   3.015


  8 in total

1.  Monitoring exposure of nursing and pharmacy personnel to cytotoxic drugs: urinary mutation assays and urinary platinum as markers of absorption.

Authors:  S Venitt; C Crofton-Sleigh; J Hunt; V Speechley; K Briggs
Journal:  Lancet       Date:  1984-01-14       Impact factor: 79.321

2.  Determination of platinum in blood by adsorptive voltammetry.

Authors:  O Nygren; G T Vaughan; T M Florence; G M Morrison; I M Warner; L S Dale
Journal:  Anal Chem       Date:  1990-08-01       Impact factor: 6.986

3.  Carcinogenicity of antitumor cis-platinum(II) coordination complexes in the mouse and rat.

Authors:  W R Leopold; E C Miller; J A Miller
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

4.  Platinum in the human diet, blood, hair and excreta.

Authors:  G T Vaughan; T M Florence
Journal:  Sci Total Environ       Date:  1992-01-01       Impact factor: 7.963

5.  cis-Diamminedichloroplatinum(II)-induced DNA adducts in peripheral leukocytes from seven cancer patients: quantitative immunochemical detection of the adduct induction and removal after a single dose of cis-diamminedichloroplatinum(II).

Authors:  A M Fichtinger-Schepman; A T van Oosterom; P H Lohman; F Berends
Journal:  Cancer Res       Date:  1987-06-01       Impact factor: 12.701

6.  Kinetics of cis-dichlorodiammineplatinum.

Authors:  P E Gormley; J M Bull; A F LeRoy; R Cysyk
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

7.  Prevalence of respiratory allergy in a platinum refinery.

Authors:  U Bolm-Audorff; H G Bienfait; J Burkhard; A H Bury; R Merget; G Pressel; G Schultze-Werninghaus
Journal:  Int Arch Occup Environ Health       Date:  1992       Impact factor: 3.015

8.  Mutagenic activity of some platinum and palladium complexes.

Authors:  Y Uno; M Morita
Journal:  Mutat Res       Date:  1993-02       Impact factor: 2.433

  8 in total
  11 in total

Review 1.  Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs.

Authors:  P J Sessink; R P Bos
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

2.  Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device.

Authors:  Paul J M Sessink; Thomas H Connor; James A Jorgenson; Timothy G Tyler
Journal:  J Oncol Pharm Pract       Date:  2010-02-15       Impact factor: 1.809

Review 3.  Environmental monitoring by surface sampling for cytotoxics: a review.

Authors:  Petit Marie; Curti Christophe; Roche Manon; Montana Marc; Bornet Charleric; Vanelle Patrice
Journal:  Environ Monit Assess       Date:  2017-01-06       Impact factor: 2.513

4.  Occupational exposure to cytotoxic drugs in two UK oncology wards.

Authors:  E Ziegler; Howard J Mason; P J Baxter
Journal:  Occup Environ Med       Date:  2002-09       Impact factor: 4.402

5.  Reduction in Surface Contamination With Cyclophosphamide in 30 US Hospital Pharmacies Following Implementation of a Closed-System Drug Transfer Device.

Authors:  Paul J M Sessink; Jason Trahan; Joseph W Coyne
Journal:  Hosp Pharm       Date:  2013-03

6.  The impact of vehicular fallout on the Pra estuary of Ghana (a case study of the impact of platinum group metals (PGMs) on the marine ecosystem).

Authors:  D K Essumang; D K Dodoo; C K Adokoh
Journal:  Environ Monit Assess       Date:  2007-12-11       Impact factor: 2.513

7.  Urinary excretion of platinum from platinum industry workers.

Authors:  R Schierl; H G Fries; C van de Weyer; G Fruhmann
Journal:  Occup Environ Med       Date:  1998-02       Impact factor: 4.402

8.  Long-term platinum excretion in patients treated with cisplatin.

Authors:  R Schierl; B Rohrer; J Hohnloser
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

9.  Cisplatin and oxaliplatin surface contamination in intensive care units (ICUs) and hospital wards during attendance of HIPEC patients.

Authors:  K-E Schenk; R Schierl; M Angele; A Burkhart-Reichl; G Glockzin; A Novotny; D Nowak
Journal:  Int Arch Occup Environ Health       Date:  2016-05-03       Impact factor: 3.015

10.  Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.

Authors:  E E M Brouwers; A D R Huitema; E N Bakker; J W Douma; K J M Schimmel; G van Weringh; P J de Wolf; J H M Schellens; J H Beijnen
Journal:  Int Arch Occup Environ Health       Date:  2007-03-22       Impact factor: 3.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.